insights_auto
Prečo akcie AXGN stúpli 2,64%?
Preskúmať podrobnejšiechevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
36,17 USD
arrow_upward
+2,64%(+0,93) 1 d.
36,88 USD
arrow_upward
+1,96% (+0,71)bedtimePo uzavretí
Zavreté: 20. 10., 16:00:01 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre AXGN…
Otvoriť
35,71 USD
Vysoká
36,84 USD
Nízka
35,56 USD
Trh. kap.
2,12 mld.
Priem. obj.
1,50 mil.
Objem
0,00
Max. za 52 týž.
52,91 USD
Min. za 52 týž.
16,78 USD
Výnosy na akciu
-0,68 USD
Beta
1,17
Akcie v obehu
58,67 mil.
Počet zamestnancov
622
Otvoriť
35,71 USD
Vysoká
36,84 USD
Nízka
35,56 USD
Trh. kap.
2,12 mld.
Priem. obj.
1,50 mil.
Objem
0,00
Max. za 52 týž.
52,91 USD
Min. za 52 týž.
16,78 USD
Výnosy na akciu
-0,68 USD
Beta
1,17
Akcie v obehu
58,67 mil.
Počet zamestnancov
622
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
PR Newswire
·
pred 46 minútami
FF EAI Robotics Ecosystem Inc. Announces Details for Its Listing Ceremony and Nasdaq Investor Day, Taking Place on Monday, Oct. 26, at Nasdaq's MarketSite in NYC
Yahoo Finance
·
pred 1 hodinou
How Long Could You Wait for the S&P 500 to Recover From a 10% Drop?
Moomoo
·
pred 1 hodinou
NYSE Is Getting Trounced in the Battle for Wall Street's Biggest IPOs -- WSJ
Investor's Business Daily
·
pred 7 minútami
Dow Jones Futures: AI Stocks Jump On SpaceX, Supermicro; Tesla, Meta On Deck
Profil
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Informácie o subjekte AxoGen, Inc Common Stock
Generálny riaditeľ-
Zamestnanci622
Dátum založenia2002
Hlavné sídloAlachua, Florida, Spojené štáty americké
Odvetvie-